Related references
Note: Only part of the references are listed.Cancer Statistics, 2010
Ahmedin Jemal et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2010)
Impact of clinical factors, including a point-of-care nuclear matrix protein-22 assay and cytology, on bladder cancer detection
Yair Lotan et al.
BJU INTERNATIONAL (2009)
Net reclassification improvement and decision theory
Andrew J. Vickers et al.
STATISTICS IN MEDICINE (2009)
Decision Analysis for the Evaluation of Diagnostic Tests, Prediction Models, and Molecular Markers
Andrew J. Vickers
AMERICAN STATISTICIAN (2008)
Urinary cytology and nuclear matrix protein 22 in the detection of bladder cancer recurrence other than transitional cell carcinoma
Georg C. Hutterer et al.
BJU INTERNATIONAL (2008)
Impact of risk factors on the performance of the nuclear matrix protein 22 point-of-care test for bladder cancer detection
Yair Lotan et al.
BJU INTERNATIONAL (2008)
Variability in the performance of nuclear matrix protein 22 for the detection of bladder cancer
Shahrokh F. Shariat et al.
JOURNAL OF UROLOGY (2006)
Nomograms including Nuclear Matrix Protein 22 for prediction of disease recurrence and progression in patients with Ta, T1 or CIS transitional cell carcinoma of the bladder
SF Shariat et al.
JOURNAL OF UROLOGY (2005)
Risk stratification for bladdertumor recurrence, stage and grade by urinary nuclear matrix protein 22 and cytology
SF Shariat et al.
EUROPEAN UROLOGY (2004)
Share Paper
